DECISION-Project

Exciting news! Sara Palomino Echeverría et al. just published their work on #ClustALL, a robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated #cirrhosis. Published in the renowned Journal of Translational Medicine. ✨ #Openaccess via 🔓 https://lnkd.in/dKZexXhE Estefanía Huergo Iglesias Asier Ortega Legarreta Eva Maria Uson Ferran Aguilar Parera Carlos de la Peña-Ramirez Cristina López Vicario Carlo Alessandria Wim Laleman Alberto Queiroz Farias Richard Moreau Jesper Tegner Jonel Trebicka Narsis Aftab Kiani Núria Planell Pierre-Emmanuel Rautou David Gomez-Cabrero Navarrabiomed, biomedical research centre European Foundation for the Study of Chronic Liver Failure (EF CLIF) European Liver Patients' Association - ELPA EASL | The Home of Hepatology #hepatology #bioinformatics #stratification #acutedecompensation #liver

The ➡️ Inflammation and liver disease group ⬅️ led by Joan Clarià study the molecular and cellular mechanisms of the #inflammatory response in #liver diseases, especially in the study of lipid-mediated inflammatory mediators, so-called lipid mediators 👉 https://lnkd.in/dfk5Pz3D

Acute on chronic liver failure

🌟 Exciting news from the DECISION-Project! The first patient has been enrolled at Hôpital Beaujon, Clichy, France in the COMBAT Trial! This EU-funded Phase II clinical trial will explore a novel combinatorial therapy with albumin and enoxaparin for decompensated cirrhosis. 🔊“We are excited to begin the COMBAT Trial and are hopeful that the combination of albumin and enoxaparin will offer a new therapeutic option for patients with decompensated cirrhosis. Our ultimate goal is to reduce mortality and improve quality of life for these patients.” - Prof. Dr Paolo Caraceni, Principal Investigator of the COMBAT Trial 🔊“The initiation of the COMBAT Trial is a testament to the hard work and dedication of our researchers and partners. We are grateful to the patients who are participating in this study and look forward to advancing our understanding of albumin and enoxaparin through this clinical trial." - Prof. Dr Pierre-Emmanuel Rautou, Scientific coordinator of DECISION 👉Read the full press release: https://lnkd.in/ez97vhyd

Researchers in the DECISION-Project develop ClustALL, a new tool that identifies patient subgroups for personalized management of acutely #decompensatedcirrhosis. Learn more about the potential clinical applications of this stratification method: https://lnkd.in/dA3tiYV5 Navarrabiomed, biomedical research centre

🔈 BIG NEWS! DECISION has enrolled the first patient at Hôpital Beaujon, Clichy, France in the COMBAT Trial, a multicenter, randomized, open-label, Phase II clinical trial. This trial is a crucial component of the DECISION project, which aims to transform the treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF), investigating albumin and enoxaparin, a potential combinatorial therapy for decompensated cirrhosis. Read more in our press release: https://lnkd.in/dcsrwc54 Pierre-Emmanuel Rautou Greater Paris University Hospitals - AP-HP CARACENI Paolo Alma Mater Studiorum – Università di Bologna European Foundation for the Study of Chronic Liver Failure (EF CLIF) EASL | The Home of Hepatology #COMBATtrial #hepatology #cirrhosis #decompensation #ACLF #liver #Albumin #Enoxaparin #ClinicalTrial #PhaseIItrial #SciComm 

#SneakPeek! Let's continue exploring the upcoming special edition on acute-on-chronic liver failure (#ACLF) and acute decompensation (AD) of cirrhosis in Liver International! ✨ As a sneak peek, we are excited to share some of the reviews and articles that will be cited in this special edition! The sixth review is: Shantha Valainathan, Qing Xie, Vicente Arroyo, Pierre-Emmanuel Rautou. Prognosis algorithms for acute decompensation of cirrhosis and ACLF. Liver Int 2024. 🔓 https://lnkd.in/dCeHwTvV 🔑 Key points * CLIF-C AD score is a score developed and validated for patients with acute decompensation of cirrhosis without ACLF. * For patients with ACLF, three different scoring system are widely used, namely the CLIF-C ACLF score, the AARC score and the NACSELD score. * Predictive value of currently available scores can still be improved. * Multiomics analyses may help develop novel tools to improve prediction of patients outcome. #decompensation #cirrhosis #Liver #Hepatology European Foundation for the Study of Chronic Liver Failure (EF CLIF)

#SneakPeek! Let's continue exploring the upcoming special edition on acute-on-chronic liver failure (#ACLF) and acute decompensation (AD) of #cirrhosis in Liver International! ✨ As a sneak peek, we are excited to share some of the reviews and articles that will be cited in this special edition! The fifth review is: Peter Lemmer, Jan-Peter Sowa, Yesim Bulut Pavel Strnad (partner site Uniklinik RWTH Aachen), Ali Canbay: Mechanisms and aetiology-dependent treatment of acute liver failure. Liver Int 2023. 🔓 https://lnkd.in/dDktyDF9 🔑 Key points: * Acute liver failure (ALF) has a high mortality of about 30% and can quickly lead to death despite maximum therapeutic intervention. * On a cellular level, ALF is characterized by massive hepatocyte death due to different types of cellular demise. * In the past decades, there has been a shift concerning the predominant etiologies, with drug-induced liver injury as the most common cause in the Western World today. * Therapy of ALF comprises intensive care medicine, aetiology-specific therapies, and in cases where ALF is irreversible. emergency liver transplantation (ELT). * ELT as therapeutic option is strongly limited by organ shortage. #clinicalmanagement #hepatology #treatment #liverfailure

🌍✨ The EASL Congress 2024 in Milan was a resounding success, and I am thrilled to share that the recordings are now available on demand on the EASL Campus website! 🌟 https://lnkd.in/egU6swdb This year, we were privileged to welcome 8,000 attendees from 120 countries, fostering an incredible exchange of knowledge and ideas. With 2,000 abstracts presented, the congress showcased cutting-edge research and advancements in hepatology. For those who couldn't join us in Milan, or for anyone wanting to revisit the insightful sessions, the on-demand recordings offer a valuable resource to stay up-to-date with the latest in the field. Explore the wealth of knowledge from EASL Congress 2024: https://lnkd.in/egU6swdb #EASLCongress 2024 #Hepatology #MedicalResearch #GlobalHealth #EASLCampus Debbie Shawcross Ana Lleo Ben Hainsworth Carina Schmidt Olga KRÜGER Massimo Pinzani Francesco Negro Sven Francque Francesco Paolo Russo European Liver Patients' Association - ELPA MSc Milan Mishkovikj, M.A.

Open calls 💰 and project highlights 🌟! ▶️ Have a peek into the current edition of the concentris newsletter 👀: https://lnkd.in/dvbsaK3G 👉 #AI in #MentalHealth Summit (1-2 July) 👉 8th EUFAMI Congress (21-22 June) 👉 DISCOVERER project leads to @ATLAS_CRC1667 👉 3 #Horizon2020 liver projects featured at #EASLCongress in Milan 👉 Successful PANCAID Steering Committee Meeting in Stockholm 👉 Open #funding calls European Health and Digital Executive Agency (HaDEA) Bundesministerium für Bildung und Forschung EASL | The Home of Hepatology European Liver Patients' Association - ELPA European Foundation for the Study of Chronic Liver Failure (EF CLIF) Pancreatic Cancer Europe environMENTAL EU Project A-TANGO DECISION-Project MICROB-PREDICT EBRAINS Deutsches Zentrum für Psychische Gesundheit (DZPG) Dr. Ameli Schwalber Nina Donner (PhD) Nina Karguth Tamara Breitinger Tassilo Steinmann Timo Lowinger Sonja Leissner Dr. Sara Stöber Dennis Cleff Jessica Jones Juliane Dittrich Barbara Heisserer Arthur Mulle Regina Puga-Hertzsch Vanessa Köhler Dr. Christiana Krammer Andrea Wohner Alexander von Humboldt Foundation Max Planck Society Helmholtz Munich Max Planck Institute of Psychiatry MPI-CBG - Max Planck Institute of Molecular Cell Biology and Genetics Charité - Universitätsmedizin Berlin Technical University of Munich Ludwig-Maximilians-Universität München